<DOC>
	<DOCNO>NCT02576431</DOCNO>
	<brief_summary>Phase II , multi-center , open-label study patient advance solid tumor harbor fusion NTRK1 , NTRK2 NTRK3 .</brief_summary>
	<brief_title>Study LOXO-101 Subjects With NTRK Fusion Positive Solid Tumors ( NAVIGATE )</brief_title>
	<detailed_description>This Phase II , multi-center , open-label study patient advance solid tumor harbor fusion NTRK1 , NTRK2 NTRK3 . Patients NTRK1 , NTRK2 NTRK3 fusion-positive cancer identify molecular assay . LOXO-101 administer 100mg twice daily ( BID ) , cycle consist 28 day dose administered continuous basis . The study include 8 cohort patient tumor bear NTRK fusion , include non small cell lung cancer , thyroid cancer , sarcoma , colorectal cancer , salivary gland cancer , biliary cancer primary CNS tumor , well cohort enroll patient include histology list .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<criteria>Key 1 . Locallyadvanced metastatic malignancy NTRK1 , NTRK2 NTRK3 gene fusion , identify molecular assay routinely perform CLIA similarlycertified laboratory . 2 . Subjects must receive prior standard therapy appropriate tumor type stage disease , opinion Investigator , would unlikely tolerate derive clinical benefit appropriate standard care therapy . 3 . Subjects must least one measurable lesion define RECIST 1.1 ( Eisenhauer 2009 ) . Subjects without RECIST measurable disease ( e.g. , evaluable disease ) eligible enrollment Cohort 8 , regardless tumor type . Subjects Cohort 7 ( primary CNS tumor ) meet follow criterion : Have receive prior treatment include radiation and/or chemotherapy , radiation complete &gt; 12 week prior C1D1 therapy . Have ≥ 1 site bidimensionally measurable disease ( confirm magnetic resonance image [ MRI ] evaluable RANO criterion ) , size least one measurable lesion ≥ 1 cm dimension note one imaging slice . Imaging study perform within 28 day enrollment stable dose steroid medication least 5 day immediately image study . 4 . Adequate organ function define follow criterion : Serum aspartate transaminase ( AST ) serum alanine transaminase ( ALT ) &lt; 2.5 upper limit normal ( ULN ) , AST ALT &lt; 5 ULN liver function abnormality due underlying malignancy . Total bilirubin &lt; 2.0 ULN . Subjects know history Gilberts Disease isolate elevation indirect bilirubin eligible . Serum creatinine &lt; 2.0 ULN OR estimate glomerular filtration rate ≥ 30 mL/minute use CockroftGault formula . 5 . Ability swallow capsule , Key 1 . Symptomatic unstable brain metastasis . ( Note : Subjects asymptomatic brain metastasis eligible participate study ) . Subjects primary CNS tumor eligible . 2 . Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>NTRK Fusion Positive</keyword>
	<keyword>LOXO-101</keyword>
	<keyword>Loxo</keyword>
	<keyword>TRK</keyword>
	<keyword>TRK Fusion</keyword>
	<keyword>NTRK1</keyword>
	<keyword>NTRK2</keyword>
	<keyword>NTRK3</keyword>
	<keyword>TRKA</keyword>
	<keyword>TRKB</keyword>
	<keyword>TRKC</keyword>
	<keyword>ETV6</keyword>
	<keyword>NTRK</keyword>
</DOC>